Company Overview and News

0
Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

2018-07-31 globenewswire
Osaka, Japan and Leuven, Belgium, July 31, 2018, 8 a.m. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ("Takeda") and TiGenix NV ("TiGenix") today announced that Takeda has acquired all outstanding ordinary shares ("Ordinary Shares") (including Ordinary Shares represented by American Depositary Shares ("ADSs")) and warrants ("Warrants", and together with the Ordinary Shares and the ADSs, the "Securities") of TiGenix following the expiration of the squeeze-out period.
4502 TIG TGXSF TIG

0
Takeda rondt overname van TiGenix af na het verstrijken van de Uitkoopperiode

2018-07-31 globenewswire
Osaka, Japan en Leuven, België, 31 juli 2018, 8.00 u. CEST - Takeda Pharmaceutical Company Limited (TSE: 4502) ('Takeda') en TiGenix NV ('TiGenix') hebben vandaag aangekondigd dat Takeda alle uitstaande gewone aandelen ("Gewone aandelen") (met inbegrip van Gewone aandelen vertegenwoordigd door Amerikaanse deposito-aandelen (American Depositary Shares, 'ADS'en')) en warrants ('Warrants,' en samen met de Gewone aandelen en de Warrants, de 'Effecten') van TiGenix heeft verworven na het verstrijken van de uitkoopperiode.
4502 TIG TGXSF TIG

0
Takeda termine son acquisition de TiGenix suite à l'expiration de la période de retrait

2018-07-31 globenewswire
Osaka, Japon et Louvain, Belgique, le 31 juillet 2018, 8 h 00 CEST - Takeda Pharmaceutical Company Limited (TSE : 4502) (« Takeda ») et TiGenix NV (« TiGenix ») ont annoncé aujourd'hui que Takeda a fait l'acquisition de toutes les actions ordinaires en circulation (« Actions ordinaires ») (y compris les Actions ordinaires représentées par American Depositary Shares (« ADS »)) ainsi que tous les warrants (« Warrants », qui avec les Actions ordinaires et les ADS forment les « Sécurités ») de TiGenix suite à l'expiration de la période de retrait.
4502 TIG TGXSF TIG

0
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

2018-07-23 globenewswire
Leuven (Belgium) - July 23, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
4502 TIG TGXSF TIG

0
TiGenix: Transparantiekennisgeving overeenkomstig Artikel 14 van de wet van 2 mei 2007

2018-07-23 globenewswire
Leuven (België) - 23 juli 2018, 22:00u CET - TiGenix NV (Euronext Brussels en Nasdaq: TIG; "TiGenix") kondigt vandaag aan dat het een transparantiekennisgeving heeft ontvangen overeenkomstig Artikel 14 van de Belgische wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen.
4502 TIG TGXSF TIG

20
Mesoblast Completes Deal In China For Stem Cell Heart Therapies

2018-07-18 seekingalpha
Mesoblast Limited (MESO) announced yesterday that it had entered into a partnership with China based Tasly Pharmaceutical Group. The deal gives Tasly exclusive rights in China for Mesoblast’s allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM for the indications of Chronic Heart Failure (CHF) and MPC-25-IC for Acute Myocardial Infarction, a.k.a, heart attack. Mesoblast is currently running two Phase III trials in the U.
HTGZ ATHX MEOBF HTGC MESO TIG HTGX TIG HTGY

0
Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix

2018-07-06 globenewswire
Takeda en TiGenix maken resultaten bekend van tweede acceptatieperiode voor het vrijwillige en voorwaardelijke openbare overnamebod van TiGenix en aanvang van de vereenvoudigde uitkoop en de intentie de ADS'en uit Nasdaq te schrappen, de ADS-aanbieding te beëindigen en om de Amerikaanse meldingsverplichtingen van Tigenix te beëindigen.
4502 TIG TGXSF TIG

0
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid

2018-07-06 globenewswire
Takeda and TiGenix Announce Results of Second Acceptance Period for the Voluntary and Conditional Public Takeover Bid in respect of TiGenix and Commencement of Simplified Squeeze-out and Intention to Delist the ADSs from Nasdaq, Terminate the ADS Facility and Terminate TiGenix's U.S. Reporting Obligations
4502 TIG TGXSF TIG

0
Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix

2018-07-06 globenewswire
Takeda et TiGenix annoncent les résultats de la deuxième période d'acceptation pour l'offre publique d'acquisition volontaire et conditionnelle de TiGenix, le début du retrait simplifié et son intention de radier les ADS du Nasdaq, de mettre un terme au programme ADS et de mettre fin aux obligations de déclarations américaines de TiGenix.
4502 TIG TGXSF TIG

0
TiGenix: Transparency Information

2018-07-02 globenewswire
Leuven (Belgium) - July 2, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings.
TIG TGXSF TIG

0
TiGenix: Transparantie Informatie

2018-07-02 globenewswire
Leuven (België) - 2 juli 2018, 22:00u CET - TiGenix NV (Euronext Brussels en Nasdaq: TIG) publiceert informatie overeenkomstig artikels 15 en 18 van de wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen (de Wet) en het koninklijk besluit van 14 februari 2008 op de openbaarmaking van belangrijke deelnemingen.
TIG TGXSF TIG

0
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

2018-06-27 globenewswire
Leuven (Belgium) - June 27, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
TIG TGXSF TIG

0
TiGenix: Transparantiekennisgeving overeenkomstig Artikel 14 van de wet van 2 mei 2007

2018-06-27 globenewswire
Leuven (België) - 27 juni 2018, 22:00u CET - TiGenix NV (Euronext Brussels en Nasdaq: TIG; "TiGenix") kondigt vandaag aan dat het een transparantiekennisgeving heeft ontvangen overeenkomstig artikel 14 van de Belgische wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen.
TIG TGXSF TIG

0
TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007

2018-06-22 globenewswire
Leuven (Belgium) - June 22, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix") announced today that it received a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.
TIG TGXSF TIG

0
TiGenix: Transparantiekennisgeving overeenkomstig Artikel 14 van de wet van 2 mei 2007

2018-06-22 globenewswire
Leuven (België) - 22 juni 2018, 22:00u CET - TiGenix NV (Euronext Brussels en Nasdaq: TIG; "TiGenix") kondigt vandaag aan dat het een transparantiekennisgeving heeft ontvangen overeenkomstig artikel 14 van de Belgische wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt en houdende diverse bepalingen.
TIG TGXSF TIG

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...